MAPK8 and Parkinson disease: Our study revealed that ILA830 treatment reversed the MPTP-induced increases in phosphorylated JNK and p38, suggesting that ILA830 mitigates PD via the inhibition of the MAPK signaling pathways, thus reducing neuroinflammation.